Table 1.
Baseline Characteristics of Study Participants (N = 20)*
| Mean (SD) | |
| Age, y | 49 (8) |
| Body mass index | 29 (5) |
| HCV RNA, IU/mL | 6.49 (0.6) |
| ALT, U/mL | 81 (45) |
| Frequency (%) | |
| Male | 17 (85) |
| Race | |
| White | 13 (65) |
| Black | 6 (30) |
| Native American | 1 (5) |
| Ethnicity | |
| Hispanic | 5 (25) |
| Not Hispanic | 15 (75) |
| HCV genotype | |
| 1a | 13 (65) |
| 1b | 6 (30) |
| 3 | 1 (5) |
| Fibrosis level | |
| 1 | 2 (10) |
| 2 | 15 (75) |
| 3 | 3 (15) |
| IL28-B genotype | |
| C/C | 6 (30) |
| C/T | 11 (55) |
| T/T | 3 (15) |
| HIV-positive | 3 (15) |
| Steatosis | |
| >33% | 0 (0) |
NOTE. SD, standard deviation; HCV, Hepatitis C virus; ALT; alanine transaminase; HIV, Human immunodeficiency virus.
*3 patients had been previously treated, 2 with standard interferon and ribavirin, the other with 2 weeks of an investigational polymerase inhibitor.